MS Speaks

From PubMed (August 18, 2022), a boatload of neurologists have contributed to this paper in Neurology, entitled "Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis":


https://pubmed.ncbi.nlm.nih.gov/35977837/


It contains this statement, which seems noteworthy:

These results suggest that untreated intervals should be minimised after stopping anti-trafficking therapies (natalizumab and fingolimod).